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Abstract 
Purpose: To develop and validate a simple and selective high performance liquid chromatography 
photo diode array mass spectrometry (HPLC-PDA-MS/MS) method for simultaneous determination and 
confirmation of seven major active alkaloids (6-Hydroxy-β-Carboline-1-carboxylic acid, β-Carboline-1-
carboxylic acid, β-Carboline-1-propanoic acid, 3-Methylcanthin-5,6-dione, 4-Methoxy-3-methylcanthine-
5,6-dione, 5-Hydroxy-4-methoxycanthin-6-one, 4,5-Dimethoxycanthin-6-one) in Kumu injections (KMIs) 
Methods: For the analysis of the preparation, the optimal chromatographic condition was achieved on a 
Phenomenex Gemini C18 column with gradient elution of 25 mM aqueous ammonium acetate (pH = 4.0 
adjusted by glacial acetate acid) and acetonitrile with flow rate at 1.0 mL/min, column temperature at 35 
oC and detection wavelengths at 245, 260 and 271 nm.  
Results: Excellent linear behavior over the investigated concentration ranges was observed with 
regression coeffcient (R2) > 0.9997 for all analytes. Intra- and inter-day precisions for all studied 
constituents ranged from 0.20 to 1.80 %. Recoveries of the assayed constituents were in the range of 
98.73 to 100.34 %. The results showed the contents of these seven marker compounds differed 
significantly among different batches of KMIs both from the same and different manufacturers.  
Conclusion: The validated method was reliable, accurate, repeatable and can be applied to routine 
quality assessment of these active components in KMIs.  
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It was about seventy years ago that injections 
were introduced into traditional Chinese medicine 
(TCM) domain as a new and important dosage 
form, which has since substantially changed the 
impression of TCM from being perceived as slow 
and weak acting into one with rapid onset and 
higher efficacy [1]. TCM injections have played 
an indispensable role in emergency medicine 
today owing to its ability to bypass the first pass 
metabolism and the active ingredients can be 
directly distributed into blood circulation to exert 
rapid therapeutic effect. However, the use of 
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TCM injections is often associated with adverse 
drug reactions (ADR). The ADR of TCM 
injections can manifest as drug fever, disorders 
of skin and appendages, circulatory system 
allergy reaction, and even anaphylactic shock in 
severe case. TCM injection-associated ADR 
could occur when changing the injection products 
to that of different manufacturers or to different 
batches of the same manufacturer. This 
observation underscores the generally 
undesirable quality of TCM injection products in 
the market and the huge challenge facing quality 
control of injection form of Chinese medicine [2]. 
Kumu injection (KMI), a widely used Chinese 
herbal preparation in China and officially 
recorded in the Drug Standard of Ministry of 
Public Health of the People’s Republic of China, 
is made from a single Chinese herbal Picrasma 
quassioides (kumu in Chinese). Kumu has the 
functions of heat-clearing, detoxification, and 
anti-inflammation in Chinese medicine practice. 
Because of the above therapeutic functions, KMI 
is extensively used for the treatment of cold, 
upper respiratory tract inflection, acute tonsillitis, 
enteritis, and bacillary dysentery [3]. 
Pharmacological and phytochemical studies on 
P. quassioides and KMI have shown that 
alkaloids are the main active ingredients 
responsible for the overall therapeutic effects of 
KMI. The P. quassioides-derived alkaloids, which 
can be broadly divided into β-carboline and 
canthinones types, have shown potent activities 
against infection and abscess of respiratory, 
digestive and urinary systems [4-8]. Among 
these alkaloids, 4,5-dimethoxycanthin-6-one 
possesses therapeutic action against ulcerative 
colitis [9], 5-hydroxy-4-methoxycanthin-6-one 
exhibits inhibitory effect against tobacco mosaic 
virus [6], while 3-methylcanthin-5,6-dione shows 
significant anti-inflammatory and antioxidant 
activities [10]. Due to the biological activities of 
these alkaloids, their quantitative measurement 
in Kumu product is of great importance for its 
quality control.  
 
Several qualitative and quantitative analytical 
methods such as thin layer chromatography [11], 
gravimetry [3] and HPLC [12] have been 
developed for quality assessment of KMI. 
However, all these methods suffered from either 
low resolution, low sensitivity or identification of 
few marker constituents (less than three 
analytes) and are inadequate for revealing the 
synergistic effects and complex constituents of 
KMI. Therefore, an analytical method with 
capability for multi-targets determination is 
urgently needed to establish the quality control 
and enhance the clinical safety and efficacy of 
KMI. 
We report for the first time in this paper a new, 
simple, sensitive and reliable HPLC-PDA-MS/MS 
method for simultaneous identification and  
determination of seven major alkaloids i.e. 6-
hydroxy-β-carboline-1-carboxylic acid (a), β-
carboline-1-carboxylic acid (b), β-carboline-1-
propanoic acid (c), 3-methylcanthin-5,6-dione 
(d), 4-methoxy-3-methylcanthine-5,6-dione (e), 
5-hydroxy-4-methoxycanthin-6-one (f), 4,5-
dimethoxycanthin-6-one (g) in 20 commercial 




Chemicals and materials 
 
Acetonitrile, methanol, ammonium acetate and 
glacial acetate acid were of HPLC-grade (Merck, 
Darmstadt, Germany). LC-MS grade water was 
purchased from Fisher Scientific (Massachusetts, 
USA). Redistilled water was used for the 
preparation of two-phase mobile solvent system. 
All other reagents used in this study were of 
analytical grade from Guanghua Chemicals Co., 
Ltd (Guangzhou, Guangdong Province, China). 
 
Seven reference standards, i.e. 6-hydroxy-β-
carboline-1-carboxylic acid (a), β-carboline-1-
carboxylic acid (b), β-carboline-1-propanoic acid 
(c), 3-methylcanthin-5,6-dione (d), 4-methoxy-3-
methylcanthine-5,6-dione (e), 5-hydroxy-4-
methoxycanthin-6-one (f), 4,5-dimethoxycanthin-
6-one (g) were isolated in our laboratory from the 
stems of P. quassioides and their identities were 
verified by ESI-MS and 1H and 13C-NMR 
spectrometric techniques and comparing with 
literature data [13,14]. The purity of each 
compound is higher than 98% based on HPLC-
PDA purity test. The chemical structures of the 
above-mentioned alkaloids are shown in Figure 
1. 
 
Negative control preparation (NC) and a total of 
20 batches of KMIs were provided by Qingfeng 
Pharmaceutical Company (Ganzhou, Jiangxi 
Province, China) and Wannianqing 
Pharmaceutical Company (Shantou, Guangdong 
Province, China). 
 
HPLC system and conditions 
 
Shimadzu LC-20A HPLC system (Shimadzu, 
Kyoto, Japan) comprising of a SPD-M20A PDA 
detector, a LC-20AT pump, a SIL-20AC 
automatic sampler, and a CTO-20A thermostatic 
column compartment was applied for 
chromatographic analysis. The separation was 
performed on Gemini C18 column (4.6 x 250 mm, 
5 μm, Phenomenex Inc., CA, USA) protected by 
a Security Guard C18 guard column (4.0 x 3.0  
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Ⅲ OCH3 OCH3 55.51 281.2 [M+H]+, 303.0 [M+Na]+, 266.0 
[M+H-CH3]+ 
      Figure 1: Chemical structures and MS data of the seven alkaloids 
mm, 5 μm, Phenomenex Inc.,CA, USA) with a 
flow rate of 1.0 mL/min, temperature at 35 oC 
and injection volume of 10 μL. The mobile phase 
consisting of solvent A (25 mM aqueous 
ammonium acetate adjusted with glacial acetic 
acid to pH 4.0) and solvent B (acetonitrile) was 
used to elute the targets with the gradient mode 
(0-30 min: 12% B → 15% B; 30-50 min: 15% B 
→ 45% B; 50-55 min: 45% B → 12% B; 55-60 
min: 12% B). The absorption spectra of the 
compounds were recorded from 190 to 400 nm. 
The detection wavelengths were set at 245 nm 
for compounds c, d e, f and g, 260 nm for 
compound b, and 271 nm for compound a. 
 
LC-MS system and conditions 
 
Agilent G6410 Triple Quad LC/MS (Agilent 
Technologies, MA, USA) was used for mass 
spectrometric measurements. The same 
separation conditions as described in HPLC-PDA 
analysis were used. By solvent splitting, 0.5 
mL/min portion of the column effluent was 
delivered into the ion source of the mass 
spectrometer. Data acquisition was performed on 
a MassHunter software system. The conditions 
of MS analysis were as follows: dry gas (N2) flow 
rate, 10 L/min; dry gas temperature, 325 oC; 
nebulizer pressure, 35 psi; source voltage, 4000 
V. The mass spectrometric data was acquired 
from m/z 100 to 1000 in positive ion mode. 
 
Preparation of standard solutions and sample 
solutions 
 
A mixed standard stock solution containing the 
seven analytes was prepared by dissolving each 
standard in methanol to obtain the 
concentrations of 30 μg/mL for 6-hydroxy-β-
carboline-1-carboxylic acid (a), 153 μg/mL for β-
carboline-1-carboxylic acid (b), 22.8 μg/mL for β-
carboline-1-propanoic acid (c), 11.4 μg/mL for 3-
methylcanthin-5,6-dione (d), 7.2 μg/mL for 4-
methoxy-3-methylcanthine-5,6-dione (e), 12 
μg/mL for 5-hydroxy-4-methoxycanthin-6-one (f) 
and 3 μg/mL for 4,5-dimethoxycanthin-6-one (g) . 
Then the stock was diluted with methanol to 1, 
2/3, 1/2, 1/3, 1/6, 1/10 and 1/30 of the original 
stock solution to serve as working solutions for 
establishing calibration curves. All of the 
standard solutions were stored at 4 oC and 
brought to room temperature before use.  
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Sample solution was prepared by filtration of an 
aliquot of the KMI through a 0.45 μm membrane 




All data analyses were carried out using 
GraphPad Prism 5 statistical software. The 
datasets were analyzed using the unpaired t-test. 





Optimization of chromatographic conditions 
 
In order to obtain chromatograms with a good 
resolution of the targeted analyte peaks, various 
chromatographic parameters were optimized. 
Five different analytical columns, i.e., Pheno-
menex Luna C18, Phenomenex Gemini C18, YMC 
Pack ODS, Agilent Zorbax SB-C18 and Waters 
Symmetry Shield RP18 were initially screened 
and the best resolution was achieved with 
Gemini C18 from Phenomenex. Suitable mobile 
phase compositions (acetonitrile-aqueous 
ammonium acetate, acetonitrile-phosphoric 
buffer, acetonitrile-aqueous sodium dodecyl 
benzene sulfonate, acetonitrile-ammonia) were 
also investigated and the acetonitrile-aqueous 
ammonium acetate system showed more 
powerful separation ability than other systems. 
The retention behavior of the compounds on the 
reversed-phase HPLC column was significantly 
affected by the pH of the mobile phase, thus 
different mobile phase pH (pH 3.5, 4.0, 4.5 and 
5.0) adjusted by glacial acid were compared and 
the peak tailing eliminated at pH 4.0. Besides, 
column temperatures (25, 30 and 35 oC) were 
also optimized. As a result, better peak shape 
was achieved at temperature of 35 oC. 
Furthermore, according to maximum absorption 
of the standards, the optimal wavelengths were 
determined to be 245 nm for compound c, d e, f 
and g, 260 nm for compound b and 271 nm for 
compound a, respectively. Typical HPLC-PDA 
chromatograms of reference compounds, KMI 
samples and negative control preparation are 
shown in Figure 2. 
 
LC-MS identity confirmation 
 
HPLC-PDA-MS/MS was employed to identify the 
seven alkaloids (compounds a-g) from KMI. By 
comparison with retention times, UV spectra 
data, precursor ions, and diagnostic fragment 
ions of the authentic compounds, seven alkaloids 
in HPLC chromatogram of KMI were 
unambiguously identified as 6-hydroxy-β-
carboline-1-carboxylic acid (peak a), β-carboline-
1-carboxylic acid (peak b), β-carboline-1-
propanoic acid (peak c), 3-methylcanthin-5,6-
dione (peak d), 4-methoxy-3-methylcanthine-5,6-
dione (peak e), 5-hydroxy-4-methoxycanthin-6-
one (peak f) and 4,5-dimethoxycanthin-6-one 
(peak g), respectively (Figure 2). As listed in 
Figure 1, quasi-molecular ions (M+H)+ and 
(M+Na)+ were observed for all the investigated 
compounds. Their fragmentation patterns 
matched well with their chemical structures. The 
successful identification of the seven compounds 
is of importance in establishing an accurate and 
feasible method for the quality control of this 
preparation. 
 
Calibration curves, LODs and LOQs 
 
The calibration curves were performed with 
working solutions at 7 different concentrations 
mentioned above in triplicate. The regression 
equations were calculated using the formula y = 
ax + b, where y and x were peak area and 
concentration (μg/mL), respectively. The working 
solutions were further diluted to a series of 
concentrations with methanol to calculate the 
limits of detection (LODs) and limits of 
quantification (LOQs) when signal-to-noise ratio 
(S/N) amounted to 3 and 10, respectively. Good 
linearity (R2 > 0.9997) was achieved within the 
investigated ranges for all the analytes. The 
LODs of seven alkaloids ranged from 0.022 to 
0.345 μg/mL and LOQs were within 0.073-1.153 
μg/mL (Table 1). 
 
Precision, repeatability, stability and 
accuracy 
 
Intra-day and inter-day variations were chosen to 
measure the precision of the developed method 
by analyzing 1, 1/3, 1/10 dilutions of the mixed 
standard solution. The intra-day and inter-day 
precisions were determined by assaying 
standard solutions at the three concentrations in 
six replicates within a single day and once a day 
for three sequential days, respectively. The 
RSDs of intra-day and inter-day precisions for all 
the components under investigation were less 
than 2% (Table 2). 
 
Repeatability was investigated by analyzing six 
independently prepared solutions (No. 
20110321) and each of them was injected into 
the apparatus at 0, 4, 8, 12, 24 and 48 h, 
respectively, to determine the stability of the 
solution. The RSDs of repeatability and stability 
of the seven compounds were all less than 3% 
(Table 2). 
 
Accuracy was determined by recovery test. The 
known quantities of the marker compounds were  
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Figure 2: Comparative chromatograms of representative KMI samples (S, 20110321), mixed standard solution 
(Std) and negative control preparation (NC) in different wavelengths: (A) 271 nm; a represent 6-Hydroxy-β-
Carboline-1-carboxylic acid; (B) 260 nm; b represent β-Carboline-1-carboxylic acid; (C) 245 nm; c, d, e, f, g 
represent β-Carboline-1-propanoic acid, 3-Methylcanthin-5,6-dione 4-Methoxy-3-methylcanthine-5,6-dione, 5-
Hydroxy-4-methoxycanthin-6-one and 4,5-Dimethoxycanthin-6-one respectively. 
 
spiked to the known aliquots of the sample 
solution (No. 20110321) that had previously been 
analyzed. Recovery was between 98.73% and 
100.34% with RSDs less than 3% for all the 
seven marker compounds (Table 2). 
 
The validation results strongly indicated that the 
HPLC-PDA method was reproducible and 
suitable for simultaneous quantitation of seven 
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         Table 1: Results of regression analysis on calibration curves 
 





A y=25573.00x - 121.38 0.9997 1.00～30.00 0.223 0.751 
B y =50207.91 x - 188245.94 0.9999 5.10～153.00 0.345 1.153 
C y =87367.65 x + 12118.45 0.9999 0.76～22.80 0.065 0.220 
D y =57092.13 x -1267.49 0.9997 0.38～11.40 0.041 0.140 
E y =81613.66 x - 4695.97 1.0000 0.24～7.20 0.039 0.132 
F y =49848.43 x - 4880.84 0.9999 0.40～12.00 0.047 0.154 
G y =31433.97 x + 771.15 0.9998 0.10～3.00 0.022 0.073 
 













RSD (%) (n=6) 
Inter-day 






3.00 1.03 0.87 
0.76 0.94 99.95 1.87 10.00 1.05 0.64 
30.00 0.68 0.54 
b 
15.30 0.92 0.67 
0.60 1.35 99.73 2.14 51.00 1.80 1.48 
153.00 1.04 0.70 
c 
2.28 1.30 1.59 
2.20 1.56 98.73 1.98 7.60 1.74 1.11 
22.80 1.35 1.15 
d 
1.14 0.64 0.52 
0.40 0.48 100.33 1.23 3.80 0.49 0.39 
11.40 0.55 0.47 
e 
0.72 0.46 0.51 
0.82 0.85 100.34 1.65 2.40 0.88 0.77 
7.20 0.54 0.56 
f 
1.20 0.20 0.36 
0.37 0.62 99.59 1.38 4.00 0.81 0.67 
12.00 0.77 0.70 
g 
0.30 0.66 0.64 
0.34 0.58 99.97 0.85 1.00 0.34 0.98 




The proposed method was subsequently applied 
to simultaneously determine the seven alkaloids 
in 20 batches of commercially-available KMI from 
two manufacturers, and the contents of the 
investigated constituents are tabulated in Table 
3, in which 6-hydroxy-β-carboline-1-carboxylic 
acid (a), β-carboline-1-carboxylic acid (b) and β-
carboline-1-propanoic acid (c) were observed to 
be more abundant than the rest four marker 
constituents among all the 20 batches of KMI 
samples. However, there were large differences 
between the samples of the two origins, which 
not only manifested in that β-carboline-1-
carboxylic acid (b) was highest in content, 
accounting for about 60% of the total seven 
alkaloids among the samples from Qingfeng 
while β-carboline-1-propanoic acid (c) was the 
most abundant accounting for approximately 
40% of the seven analytes in samples from 
Wannianqing. Also the total contents of the 
seven target compounds showed significant 
variations between samples from the different 
manufacturers according to statistical results. 
Furthermore, the average contents of 
compounds a-e were much higher among 
samples from Qingfeng than those from 
Wannianqing with only exception of β-carboline-
1-propanoic acid (c). Also, large quality 
fluctuations obviously existed among the 




Based on the results of these analyses of the 
contents of the seven bioactive compounds of 
KMI, large quality variations among all these 
products obviously existed among the samples 
both from the same and different manufacturers, 
which may arise from the different sources of the 
raw herbal materials, material collection if plant 
were at different times of the year, disparity in 
preparation technology in different factories, and 
lack of effective quality control method to 
maintain the quality consistency of the 
preparation. All these factors  
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Table 3: Contents (μg/mL) of the seven alkaloids in KMI 
 
No. Batch No. source 
Content of Analytes (mean ± SD, μg/mL n=3)  
a b c D E f g Total 
1 20110321 Qingfeng 27.61±0.03 94.55±0.24 13.27±0.24 5.15±0.02 2.51±0.01 6.96±0.05 2.80±0.02 152.85 
2 20110429 Qingfeng 18.52±0.12 75.18±0.08 10.79±0.04 4.01±0.01 1.98±0.02 4.40±0.08 1.59±0.03 116.47 
3 20110616 Qingfeng 19.34±0.01 64.61±0.04 11.08±0.01 3.64±0.05 1.72±0.06 4.35±0.06 2.02±0.02 106.76 
4 20110729 Qingfeng 27.97±0.09 93.84±0.10 17.14±0.04 4.57±0.02 2.66±0.01 7.13±0.04 3.09±0.01 Z 156.40 
5 20110823 Qingfeng 6.64±0.02 27.33±0.01 4.39±0.01 1.12±0.01 0.41±0.01 0.29±0.01Z 0.26±0.00 40.44 
6 20110919 Qingfeng 19.75±0.01 49.68±0.11 9.03±0.01 2.70±0.03 1.19±0.01 2.34±0.02 1.19±0.00 85.88 
7 20111008 Qingfeng 12.10±0.01 35.01±0.11 6.56±0.01 1.76±0.01 0.71±0.02 0.63±0.03 0.50±0.01 57.27 
8 20111127 Qingfeng 11.97±0.08 36.08±0.28 4.81±0.03 1.12±0.01 0.46±0.01 0.46±0.02 0.47±0.02 55.37 
9 20120105 Qingfeng 11.83±0.01 36.13±0.08 6.78±0.04 1.73±0.02 0.66±0.01 0.29±0.00Z 0.42±0.00 57.83 
10 20120107 Qingfeng 7.72±0.03 24.97±0.14 4.85±0.01 0.92±0.01 0.45±0.01 0.38±0.00 0.51±0.01 39.80 
11 20110317 Wannianqing 10.12±0.05 16.90±0.01 24.19±0.07 Z 1.70±0.00 – 2.41±0.07 0.96±0.00 56.28 
12 20110320 Wannianqing 14.79±0.03 48.18±0.42 41.49±0.04 Z 2.24±0.06 0.34±0.01 3.35±0.08 3.26±0.03 Z 113.65 
13 20110418 Wannianqing 5.97±0.09 4.70±0.00 Z 17.01±0.03 0.50±0.00 0.25±0.01 0.93±0.00 0.38±0.01 29.74 
14 20110420 Wannianqing 4.92±0.02 4.30±0.01 Z 7.45±0.02 0.25±0.00 Z 0.18±0.00 0.59±0.01 0.11±0.00Z 17.80 
15 20110501 Wannianqing 6.21±0.07 4.58±0.01 Z 13.98±0.37 0.40±0.01 0.22±0.00 Z 0.94±0.02 0.28±0.00 26.61 
16 20110523 Wannianqing 6.50±0.03 6.05±0.03 14.68±0.04 0.22±0.00 Z 0.25±0.01 1.58±0.03 0.16±0.00 29.44 
17 20110606 Wannianqing 9.25±0.06 14.20±0.01 29.81±0.05 Z 0.98±0.00 0.62±0.01 3.34±0.04 0.70±0.01 58.90 
18 20110616 Wannianqing 8.82±0.11 12.24±0.01 25.34±0.01 Z 0.57±0.01 0.56±0.01 1.63±0.00 0.36±0.00 49.52 
19 20110708 Wannianqing 8.76±0.09 8.12±0.00 18.01±0.06 0.60±0.01 0.17±0.00 Z 1.59±0.04 0.18±0.00 37.43 
20 20110713 Wannianqing 6.53±0.01 5.91±0.01 13.66±0.02 0.36±0.00 Z – 1.02±0.02 – 27.47 
(–) Lower than test limit and could not be quantified;  Z Out of linear range. 
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would definitely affect their therapeutic efficacies 
and even safety. It is also worth noting that 
compound d, e, f, g believed as important 
bioactive compounds [6,9,10], were prone to 
huge loss during the preparation due to their 
small polar and weak water-soluble properties. 
There is certainly room for proper care in plant 
collection, processing and technical improvement 
in the preparation of the KMI to reduce the loss 




Efficient and reliable analytical protocols to 
evaluate and control the quality of TCM injections 
are urgently needed to minimize the ADR 
associated with the use of this dosage form of 
Chinese herbal products. We have successfully 
developed a powerful and reliable analytical 
method for quality evaluation of KMI through 
identification and simultaneous quantitation of 
seven major alkaloids of KMI, namely 6-hydroxy-
β-carboline-1-carboxylic acid, β-Carboline-1-
carboxylic acid, β-carboline-1-propanoic acid, 3-
methylcanthin-5,6-dione, 4-methoxy-3-methyl-
canthine-5,6-dione, 5-hydroxy-4-methoxycan-
thin-6-one, 4,5-dimethoxycanthin-6-one by 
HPLC-PDA-MS-MS. This method has been 
proven to be sensitive, accurate and reproducible 
and could provide valuable quantitative 
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